INKON Life(300143) 金融界·2025-03-30 14:49Core Viewpoint - Yingkang Life is advancing its external growth strategy by acquiring a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which is a significant step in its regional medical center layout and "1+n" strategy [1][2]. Group 1: Acquisition Details - The acquisition involves a cash payment of 357 million yuan for 51% of Changsha Kexin, which will become a subsidiary of Yingkang Life and included in its consolidated financial statements [2]. - Changsha Kexin, established in September 2015, is a tertiary oncology specialty hospital with 420 beds and over 30 clinical departments, recognized as a benchmark institution for cancer prevention and treatment in Central China [2]. - In the first three quarters of 2024, Changsha Kexin reported revenues of 273 million yuan and a net profit of approximately 33.43 million yuan, with profit guarantees of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025, 2026, and 2027 respectively [2]. Group 2: Strategic Implications - The acquisition is expected to enhance Yingkang Life's capabilities in the oncology sector, contributing to sustainable growth and improved operational synergy [1][4]. - The company aims to strengthen its market competitiveness and technical depth in the oncology specialty field through the integration of resources from the newly acquired hospital [4]. - Yingkang Life's strategy focuses on high-quality development and differentiated service offerings in oncology, with projected revenues of 1.559 billion yuan in 2024, including 1.192 billion yuan from medical services and 31.9% of medical service revenue coming from oncology [3]. Group 3: Broader Industry Context - The acquisition aligns with recent policies encouraging listed companies to focus on their core businesses and utilize mergers and acquisitions to enhance development quality [5]. - Yingkang Life is leveraging policy benefits to advance its external growth strategy, aiming to create a standardized process for hospital acquisitions and management [5]. - The actual controller of Yingkang Life, Haier Group, has been expanding in the health sector, with this acquisition reflecting its deeper commitment to the clinical medicine segment [6].